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ABSTRACT
Background: Lung function determined by spirometry and the severity of dyspnea correlate weakly in asthma
patients. We attempted to determine the risk factors in asthma patients having persistent airway obstruction de-
spite of having only mild subjective symptoms, and to examine the possibility of improving FEV1 by treating
asthma on the basis of the bronchodilator change in FEV1.
Methods: We examined asthma patients in their 20s and who visited Sagamihara National Hospital for the
first time over a period of four years, by reviewing their clinical records. They underwent tests on the bronchodi-
lator change in FEV1 and a test of airway hyperresponsiveness to histamine dihydrochloride.
Results: One hundred thirty-eight subjects (mean age, 25.6 years; 51 males, 87 females; current smoking,
30.4%; history of childhood asthma, 48.6%) were enrolled. Among them, 18.8% (26138) showed persistent
airway obstruction (postbronchodilator FEV1FVC (%) <80%). Using the multiple logistic regression model, we
found that history of childhood asthma and smoking history were the significant isolated risk factors for persis-
tent airway obstruction. Moreover, we determined that the factors associated with the reversibility of airway ob-
struction in asthma patients without subjective symptoms were history of childhood asthma.
Conclusions: In this study, patients not undergoing treatment for asthma were examined. History of child-
hood asthma and smoking history may be the risk factors for persistent airway obstruction in the asthma pa-
tients with mild subjective symptoms. Tests on the bronchodilator change in FEV1 should be performed in pa-
tients with history of childhood asthma and smoking history, even if they have only mild subjective symptoms.
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INTRODUCTION
Bronchial asthma is characterized by symptoms asso-
ciated with variable airflow obstruction, airway in-
flammation, and airway hyperresponsiveness.
Asthma patients show subjective symptoms (for ex-
ample, cough, wheezing, and dyspnea) of varying se-
verity. It was reported that lung function determined
by spirometry and the severity of dyspnea correlate
weakly in asthma patients, and a blunted perception
of dyspnea by asthma patients is likely the cause of
life-threatening asthma exacerbation.1-3 Patients who
have a blunted perception of dyspnea may have air-
way remodeling due to persistent airway inflamma-
tion. Airway remodeling may lead to irreversible loss
of lung function. The most accurate method to detect
airway remodeling is bronchial biopsy. However,
bronchial biopsy is an invasive examination. There-
fore, we focused on persistent airway obstruction,
which was examined by lung function tests. The post-
bronchodilator ratio of forced exhaled volume in 1
second (FEV1) to vital capacity (VC) or forced vital
capacity (FVC) is used as a marker of persistent air-
way obstruction.4,5 We attempted to determine the
risk factors in asthma patients having persistent air-
way obstruction despite of having only mild subjec-
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tive symptoms, and to examine the possibility of im-
proving FEV1 by treating asthma on the basis of the
bronchodilator change in FEV1.
METHODS
STUDY POPULATION
We examined asthma patients with mild asthma on
the basis of subjective symptoms (excluding those
with acute exacerbation such as episodes of a pro-
gressive intensification of shortness of breath, cough,
wheezing, or chest tightness, and those with the need
for treatment with systemic corticosteroids) who did
not use controller medications, who were in their 20s,
and who visited Sagamihara National Hospital for the
first time from January 2004 to March 2008, by re-
viewing their clinical records. They underwent tests
on the bronchodilator change in FEV1 and a test of
airway hyperresponsiveness to histamine dihydro-
chloride (His) within four weeks of their first visit,
under the condition that they did not use a bron-
chodilator less than 12 hours before the test. The
condition of not using controller medications in our
study denotes not using drugs, such as inhaled corti-
costeroids (ICS), a leukotriene receptor antagonist
(LTRA), a long-acting inhaled β2 agonist (LABA),
theophylline, or sodium cromoglycate for six months,
except for a short-acting inhaled β2 agonist (SABA)
or a bronchodilator as required. The asthma diagno-
sis was made in accordance with the American Tho-
racic Society (ATS) guidelines and was determined
as episodes of paroxysms of dyspnea, wheezing, and
cough, and an increased airway hyperresponsive-
ness.6 Mild asthma symptoms were defined in accor-
dance with the following criteria: 1. asthma symp-
toms occurred less than once a week for a month, 2.
no visit to a medical institution because of asthma ex-
acerbation for one year, and 3. no hospitalization be-
cause of asthma exacerbation for three years. Exclu-
sion criteria included an abnormal shadow in chest X-
ray films, pregnancy, and other respiratory diseases.
One hundred thirty-eight asthma patients were cho-
sen on the basis of the above-mentioned criteria.
Moreover, all of the subjects were enrolled with their
written informed consent, and methods approved by
the ethnical review comittee of our hospital.
OUTCOME VARIABLES
We performed the bronchodilator change tests in
FEV1 and airway hyperresponsiveness test within
four weeks of the first visit, under the condition that
they had not used controller medications or a bron-
chodilator for more than 12 hours before the test.
Lung function was measured using a spirometer
(Auto Spiro AS-303; Minato Medical Science Co.,
Ltd., Osaka, Japan).
We conducted the bronchodilator change tests in
FEV1 using β2 agonist inhalation. A normal postbron-
chodilator FEV1FVC is more than 80%.5,7 Ras-
mussen and Mariotta have shown that airway remod-
eling is demonstrated by a low postbronchodilator
FEV1FVC, and the cut-off value defined as 80%.5,7
Persistent airway obstruction was determined as hav-
ing a postbronchodilator FEV1FVC(%) <80%. A bron-
chodilator (salbutamol, 5 mgml nebulizer solution)
was administered to the subjects. Lung function was
measured before bronchodilator administration (pre)
and 30 minutes after (post). The best FEV1FVC was
chosen from three measurements.
The airway hyperresponsiveness test was per-
formed as described by Chai et al..8 We prepared his-
tamine dihydrochloride (Sigma, St. Louis, MO, USA)
at 0.078, 0.157, 0.316, 0.625, 1.25, 2.5, 5, and 10 mg
ml by diluting it in buffered saline (pH 7.4). All anti-
asthma medications were withheld for at least 12
hours before measurement. The subjects inhaled
aerosol from a nebulizer (DeVilbiss 646; DeVilbiss,
Somerset, PA, USA; 5 Lmin) by tidal breathing for 2
min. Isotonic saline was inhaled first to obtain a base-
line measurement. Histamine dihydrochloride at in-
creasing concentrations was then inhaled until FEV1
decreased by >20% of its post-saline solution value or
until the maximum concentration was reached. Bron-
chial sensitivity was defined as the provocative con-
centration (PC) of the agonist leading to a decrease
in FEV1 by >20% (PC20). Subjects with HisPC20 of
<10 mgml were defined as being positive for airway
hyperresponsiveness. HisPC20 of more than 2000
μgml was considered to indicate a more than moder-
ate sensitivity, as determined from the severity classi-
fication based on methacholine bronchial hypersensi-
tivity (MchPC20) reported by Woolcock et al..9
STATISTICAL ANALYSES
The subjects were divided into two groups (postbro-
chochodilator FEV1FVC(%) <80% and 80%). More-
over, we classified the subjects on the basis of their
showing reversibility of airway obstruction or not.
The reversibility of airway obstruction is defined as
an FEV1 increase of more than 12% and 200 ml in
comparison with the prebronchodilator FEV1 on the
basis of the criteria of American Thoracic Society.10
We used the Mann-Whitney U test and χ2 test to de-
termine statistically significant differences. Multiple
logistic regression analysis was used to determine
the association between outcome variables and vari-
ables found to be statistically significant by univariate
analysis. We performed multiple logistic regression
analysis for each outcome variable to estimate the ad-
justed odds ratios (ORs) for gender, history of child-
hood asthma, smoking history, serum IgE level, and
HisPC20. Adjusted ORs and the corresponding 95%
confidence intervals (95% CIs) were calculated.
Analyses were conducted using SPSS 11.0 for Win-
dows (IBM Japan, Tokyo, Japan). p < 0.05 was consid-
ered statistically significant.
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Table　1　The characteristics of the subjects in the classifi -
cation based on postbronchodilator FEV1/FVC
n 138
Male/Female 51/87
Age (years)  25.6 (25.1-26.1)
Current smoking (%) 30.4
Pet ownership (%) 51.4
History of childhood asthma (%) 48.6
Onset of asthma (years)  15.2 (13.5-16.9)
Blood IgE level (IU/ml) 1362 (631-2094)
Blood eosinophil count (%)   6.6 (5.8-7.4)
FEV1 (L)  2.94 (2.83-3.04)
FEV1 (%, predicted)  89.5 (87.2-91.8)
FEV1/FVC (%)  81.3 (79.7-82.9)
Improvement rate of postbronchodilator 
FEV1 (ml)
 199 (154-243)
Improvement rate of postbronchodilator 
FEV1 (%, predicted)
  7.2 (5.6-8.9)
logHisPC20  3.11 (3.03-3.20)
Date are presented mean difference (95% CI) or percentage of
patients or number.
Table　2　The classifi cation based on postbronchodilator FEV1/FVC
Postbronchodilator
FEV1/FVC <80%
Postbronchodilator
FEV1/FVC ≥80% P-value
n 26 112 -
Postbronchodilator FEV1/FVC (%)  71.5 (68.6-74.5)  88.8 (87.9-89.8) -
Postbronchodilator FEV1 (%, predicted)  78.2 (71.8-84.7) 100.1 (97.6-102.7) -
Improvement rate of postbronchodilator FEV1 (%)  12.9 (7.8-18.0)   5.9 (4.4-7.4) <0.001
Gender · male (%) 57.7 32.1 0.015
Age (years)  26.5 (25.2-27.7)  25.4 (24.9-26.0) 0.123
Current smoking (%) 46.2 26.8 0.042
Pet ownership (%) 50.0 51.8 0.870
History of childhood asthma (%) 76.9 38.4 <0.001
Onset of asthma (years)   9.1 (5.5-12.9)  16.6 (14.8-18.4) <0.001
Blood IgE level (IU/ml) 3270 (160-6379)   865 (529-1202) 0.005
RAST house dust mite (%) 80.0 84.0 0.693
fungus (%) 12.5  7.2 0.384
pet (%) 25.0 21.2 0.579
Blood Eosinophil count (%)   7.8 (6.0-9.7)   6.4 (5.5-7.2) 0.156
Prebronchodilator FEV1 (L)  2.65 (2.42-2.87)  3.00 (2.89-3.11) 0.007
Prebronchodilator FEV1 (%, predicted)  73.7 (69.2-73.6)  93.2 (91.0-95.3) <0.001
Prebronchodilator FEV1/FVC (%)  70.1 (66.6-78.2)  83.9 (82.5-85.3) <0.001
logHisPC20  2.93 (2.70-3.16)  3.16 (3.06-3.25) 0.044
Date are presented mean difference (95% CI) or percentage of patients or number.
RESULTS
CHARACTERISTICS OF SUBJECTS
The characteristics of all the enrolled subjects and
the results of pulmonary function tests are shown in
Table 1. One hundred thirty-eight subjects (mean
age, 25.6 years; 51 males, 87 females; current smok-
ing, 30.4%; history of childhood asthma, 48.6%) were
enrolled.
EXAMINATION OF PERSISTENT AIRWAY OB-
STRUCTION
The features of the groups of postbronchodilator
FEV1FVC (%) <80% and 80% groups are shown in
Table 2. Among the subjects, 18.8% (26138) showed
persistent airway obstruction. There were no signifi-
cant differences in mean age and the percentage of
pet ownership between the two groups. Moreover,
there were no significant differences in laboratory ex-
amination results on common allergens and blood
eosinophil count. We found significant differences in
current smoking (p = 0.042), history of childhood
asthma (p < 0.001), age at onset of asthma (p < 0.001),
blood IgE level (p = 0.005), and logHisPC20 (p =
0.044) in univariate analysis. In the multiple logistic
regression model, history of childhood asthma, and
smoking history were the significant isolated risk fac-
tors for persistent airway obstruction (Table 3).
REVERSIBILITY OF AIRWAY OBSTRUCTION
The features of the two groups of subjects classified
on the basis of their showing the reversibility of air-
way obstruction or not are shown Table 4. The sub-
jects were divided into two groups (increase FEV1
12% and 200 ml group and increase FEV1 <12% or
200 ml group). Among the subjects, 23.9% (33138)
showed reversibility of airway obstruction. There
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Table　3　In the multiple logistic regression model in the 
postbronchodilator FEV1/FVC
Persistent Air Flow Limitation
(postbronchodilater 
FEV1/FVC (%) <80%)
Odds ratio (95% CI)
Gender (male) 1.49 (0.57-3.92)
History of childhood asthma 2.74 (1.02-7.31)
Current smoking 3.72 (1.21-11.45)
Blood IgE (every level be 
elevated 10 times)
1.67 (0.77-3.63)
HisPC20 (<2000 μg/ml) 1.00 (0.39-2.55)
Table　4　The classifi cation based on the increase FEV1 in comparison with the pre-bronchodilator FEV1
Increase FEV1
≥12% and 200 ml
Increase FEV1
<12% or 200 ml P-value
n 33 105
Postbronchodilator FEV1/FVC (%)  81.7 (78.7-84.6)  86.8 (85.1-88.5) <0.001
Postbronchodilator FEV1 (%, predicted)   94.1 (85.9-102.3)  96.8 (94.1-99.6) 0.022
Improvement rate of postbronchodilator FEV1 (%)  20.6 (17.5-23.7) 3.0 (2.0-4.0) <0.001
Improvement rate of postbronchodilator FEV1 (ml) 530 (442-620)  93 (62-124) <0.001
Gender · male (%) 48.5 33.3 0.117
Age (years)  26.4 (24.5-27.5)  25.4 (24.8-26.0) 0.094
Current smoking (%) 24.2 32.4 0.377
Pet ownership (%) 30.3 53.3 0.431
History of childhood asthma (%) 75.8 40.0 <0.001
Onset of asthma (years)  9.8(6.4-13.2)  16.9 (15.0-18.8) <0.001
Blood IgE level (IU/ml) 1846 (606-3087)  1210 (314-2107) 0.086
Blood Eosinophil count (%)  8.3 (6.4-10.3) 6.1 (5.2-7.0) 0.027
Prebronchodilator FEV1 (L)  2.67 (2.48-2.86)  3.02 (2.90-3.14) 0.010
Prebronchodilator FEV1 (%, predicted)  77.9 (74.5-81.4)  93.1 (90.6-95.6) <0.001
Prebronchodilator FEV1/FVC (%)  72.0 (69.0-74.9)  84.3 (82.7-85.8) <0.001
logHisPC20  2.90 (2.69-3.10)  3.18 (3.09-3.28) 0.009
Date are presented mean difference (95% CI) or percentage of patients or number.
Table　5　In the multiple logistic regression model the bron-
chodilator change in FEV1
The low bronchodilator 
change (Increase FEV1 
≥12% or 200 ml) 
Odds ratio (95% CI)
History of childhood asthma 3.49 (1.36-8.95)
Blood Eosinophil count (>6%) 1.41 (0.61-3.28)
HisPC20 (<2000 μg/ml) 2.20 (0.82-5.90)
were no significant differences in the mean age, the
percentage of pet ownership and the percentage of
subjects currently smoking between the two groups.
By univariate analysis, we found significant differ-
ences in history of childhood asthma (p < 0.001), age
at onset of asthma (p < 0.001), blood eosinophil count
(p = 0.027), and logHisPC20 (p = 0.009). In the multi-
ple logistic regression model, history of childhood
asthma was the significant isolated factors for reversi-
bility of airway obstruction (Table 5).
DISCUSSION
We examined persistent airway obstruction on the
basis of changes in postbronchodilator FEV1FVC.
The response to a bronchodilator is the simplest test
for assessing airway obstruction. It was surprising
that persistent airway obstruction conventionally
found in patients with severe asthma was also found
in patients with mild asthma symptoms. It was sug-
gested that persistent airway obstruction is associ-
ated with history of childhood asthma and current
smoking in this examination. It was reported by Ras-
mussen et al. that a low postbronchodilator FEV1VC
ratio was related to childhood asthma, male sex, air-
way hyperresponsiveness and low lung function in
childhood.4 These findings were compatible with
those of our study.
Smoking is responsible for the development and
persistence of airway inflammation. Acute exposure
to cigarette smoke triggers bronchoconstriction and
symptoms in people with asthma.11,12 Even nonsmok-
ing patients with asthma may have significant expo-
sure to passive smoke. Compared with nonsmokers
with asthma, smokers with asthma have more severe
symptoms,13,14 increased rates of hospitalization15
and accelerated decline in lung function.16,17 Particu-
larly high rates of adults presenting with acute
asthma have been noted to hospital emergency de-
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partments.15 It was considered that smoking is impli-
cated in airway damage and contributes to airway re-
modeling.18,19
Among patients with mild subjective symptoms,
23.9% showed reversibility of airway obstruction in
our study. It has been reported that 25% of bronchial
asthma patients in early stages showed an FEV1 in-
crease of more than 12% in comparison with the pre-
bronchodilator FEV1 in the reversibility test of airway
obstruction and that 23% of moderate to severe
asthma patients exhibited an incomplete reversibility
of airway obstruction.20,21 However, the exact preva-
lence of airway obstruction is unclear. In our study,
history of childhood asthma, blood eosinophilia count
and the increase in airway hyperresponsiveness were
associated with having the irreversibility of airway ob-
struction in asthma patients without subjective symp-
toms. The severity of airway hyperresponsiveness
has been shown to be an independent predictor of an-
nual decline in lung function in general population.22
Moreover, it is reported that there is a positive corre-
lation between airway hyperresponsiveness and the
rate of decrease in FEV1 in mild to moderate
asthma.23 In another study, the only independent fac-
tor associated with persistent airflow limitation was
found to be sputum eosinophilia.24 Irreversible airway
obstruction was associated with increased disease se-
verity and increased asthma-related morbidity and
mortality.25 In our study, history of childhood asthma
was associated with having the reversibility of airway
obstruction in asthma patients without subjective
symptoms. It is possible for asthma patients having
the reversibility of airway obstruction to improve
FEV1 by treatment for asthma. The bronchodilator
change tests in FEV1 may be worth in patients hav-
ing history of childhood asthma. We consider that the
reversibility of airway obstruction using bronchodila-
tor is useful to find residual airway inflammation and
structural change in asthma patients.
It is reported that most former asthma patients
who were considered to be in asthma remission
showed a persistent increase in airway responsive-
ness with or without airflow obstruction, and subjec-
tive symptoms may be insufficient to determine true
remission.26 It is difficult to determine true remission
of childhood asthma. Persistent airway obstruction
was associated with history of childhood asthma in
this study. It is possible that airway inflammation has
not disappeared completely in patients with history of
childhood asthma. In our study as well as 18.8% of pa-
tients with mild subjective symptoms showed a low
postbronchodilator FEV1VC. It is difficult to deter-
mined asthma severity on the basis of only subjective
symptoms. Early detection of persistent airway ob-
struction, particularly in asthma patients with mild
symptoms, leads to adequate therapies in the earlier
stages. In this study, patients not undergoing treat-
ment for asthma were examined. These patients may
regain their post-bronchodilator FEV1FVC 80% af-
ter anti-inflammatory treatment of asthma. History of
childhood asthma and smoking history may be the
risk factors for persistent airway obstruction in the
asthma patients with mild subjective symptoms. The
later progress needs the investigation again.
History of childhood asthma and smoking history
may be the risk factors of persistent airway obstruc-
tion in the asthma patients with mild subjective symp-
toms. Tests on the bronchodilator change in FEV1
should be performed in patients with history of child-
hood asthma and smoking history, even if they have
only mild subjective symptoms.
Our study has limitations. First, this study design
was a complete survey in our hospital but was not a
prospective study. It will be necessary to investigate
prospectively in the future. Second, we limited our
subjects to young adults with asthma because we
wanted to examine our hypothesis without the effects
of underlying diseases, aging, long-term smoking,
and long-term medication. This theme should be in-
vestigated in all age groups in the future. Third, we
were also unable to examine sputum eosinophil count
and histopathological findings, which were reported
to be superior for the monitoring of airway inflamma-
tion. We need to perform these measurements in the
future.
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